Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK, Galpharm Pioneer UK Nonprescription Omeprazole Market

This article was originally published in The Tan Sheet

Executive Summary

Galpharm Healthcare will launch a nonprescription omeprazole product under the name Galpharm Heartburn Relief in the UK "shortly," according to a spokesperson for the British firm

You may also be interested in...



Zocor Brand For Pharmacy Access Drug May Create Confusion – Galpharm

Use of the Zocor brand name for the nonprescription version of Merck's prescription statin "has the massive potential to cause confusion with [prescription] products which could have serious ramifications," Galpharm Healthcare says in comments to the UK's Medicines & Healthcare products Regulatory Agency

Zocor Brand For Pharmacy Access Drug May Create Confusion – Galpharm

Use of the Zocor brand name for the nonprescription version of Merck's prescription statin "has the massive potential to cause confusion with [prescription] products which could have serious ramifications," Galpharm Healthcare says in comments to the UK's Medicines & Healthcare products Regulatory Agency

Zocor Brand For Pharmacy Access Drug May Create Confusion – Galpharm

Use of the Zocor brand name for the nonprescription version of Merck's prescription statin "has the massive potential to cause confusion with [prescription] products which could have serious ramifications," Galpharm Healthcare says in comments to the UK's Medicines & Healthcare products Regulatory Agency

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096639

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel